Literature DB >> 28236296

Different types of dietary advice for women with gestational diabetes mellitus.

Shanshan Han1, Philippa Middleton1,2, Emily Shepherd1, Emer Van Ryswyk1, Caroline A Crowther3.   

Abstract

BACKGROUND: Dietary advice is the main strategy for managing gestational diabetes mellitus (GDM). It remains unclear what type of advice is best.
OBJECTIVES: To assess the effects of different types of dietary advice for women with GDM for improving health outcomes for women and babies. SEARCH
METHODS: We searched Cochrane Pregnancy and Childbirth's Trials Register (8 March 2016), PSANZ's Trials Registry (22 March 2016) and reference lists of retrieved studies. SELECTION CRITERIA: Randomised controlled trials comparing the effects of different types of dietary advice for women with GDM. DATA COLLECTION AND ANALYSIS: Two authors independently assessed study eligibility, risk of bias, and extracted data. Evidence quality for two comparisons was assessed using GRADE, for primary outcomes for the mother: hypertensive disorders of pregnancy; caesarean section; type 2 diabetes mellitus; and child: large-for-gestational age; perinatal mortality; neonatal mortality or morbidity composite; neurosensory disability; secondary outcomes for the mother: induction of labour; perineal trauma; postnatal depression; postnatal weight retention or return to pre-pregnancy weight; and child: hypoglycaemia; childhood/adulthood adiposity; childhood/adulthood type 2 diabetes mellitus. MAIN
RESULTS: In this update, we included 19 trials randomising 1398 women with GDM, at an overall unclear to moderate risk of bias (10 comparisons). For outcomes assessed using GRADE, downgrading was based on study limitations, imprecision and inconsistency. Where no findings are reported below for primary outcomes or pre-specified GRADE outcomes, no data were provided by included trials. Primary outcomes Low-moderate glycaemic index (GI) versus moderate-high GI diet (four trials): no clear differences observed for: large-for-gestational age (risk ratio (RR) 0.71, 95% confidence interval (CI) 0.22 to 2.34; two trials, 89 infants; low-quality evidence); severe hypertension or pre-eclampsia (RR 1.02, 95% CI 0.07 to 15.86; one trial, 95 women; very low-quality evidence); eclampsia (RR 0.34, 95% CI 0.01 to 8.14; one trial, 83 women; very low-quality evidence) or caesarean section (RR 0.66, 95% CI 0.29 to 1.47; one trial, 63 women; low-quality evidence). Energy-restricted versus no energy-restricted diet (three trials): no clear differences seen for: large-for-gestational age (RR 1.17, 95% CI 0.65 to 2.12; one trial, 123 infants; low-quality evidence); perinatal mortality (no events; two trials, 423 infants; low-quality evidence); pre-eclampsia (RR 1.00, 95% CI 0.51 to 1.97; one trial, 117 women; low-quality evidence); or caesarean section (RR 1.12, 95% CI 0.80 to 1.56; two trials, 420 women; low-quality evidence). DASH (Dietary Approaches to Stop Hypertension) diet versus control diet (three trials): no clear differences observed for: pre-eclampsia (RR 1.00, 95% CI 0.31 to 3.26; three trials, 136 women); however there were fewer caesarean sections in the DASH diet group (RR 0.53, 95% CI 0.37 to 0.76; two trials, 86 women). Low-carbohydrate versus high-carbohydrate diet (two trials): no clear differences seen for: large-for-gestational age (RR 0.51, 95% CI 0.13 to 1.95; one trial, 149 infants); perinatal mortality (RR 3.00, 95% CI 0.12 to 72.49; one trial, 150 infants); maternal hypertension (RR 0.40, 95% CI 0.13 to 1.22; one trial, 150 women); or caesarean section (RR 1.29, 95% CI 0.84 to 1.99; two trials, 179 women). High unsaturated fat versus low unsaturated fat diet (two trials): no clear differences observed for: large-for-gestational age (RR 0.54, 95% CI 0.21 to 1.37; one trial, 27 infants); pre-eclampsia (no cases; one trial, 27 women); hypertension in pregnancy (RR 0.54, 95% CI 0.06 to 5.26; one trial, 27 women); caesarean section (RR 1.08, 95% CI 0.07 to 15.50; one trial, 27 women); diabetes at one to two weeks (RR 2.00, 95% CI 0.45 to 8.94; one trial, 24 women) or four to 13 months postpartum (RR 1.00, 95% CI 0.10 to 9.61; one trial, six women). Low-GI versus high-fibre moderate-GI diet (one trial): no clear differences seen for: large-for-gestational age (RR 2.87, 95% CI 0.61 to 13.50; 92 infants); caesarean section (RR 1.91, 95% CI 0.91 to 4.03; 92 women); or type 2 diabetes at three months postpartum (RR 0.76, 95% CI 0.11 to 5.01; 58 women). Diet recommendation plus diet-related behavioural advice versus diet recommendation only (one trial): no clear differences observed for: large-for-gestational age (RR 0.73, 95% CI 0.25 to 2.14; 99 infants); or caesarean section (RR 0.78, 95% CI 0.38 to 1.62; 99 women). Soy protein-enriched versus no soy protein diet (one trial): no clear differences seen for: pre-eclampsia (RR 2.00, 95% CI 0.19 to 21.03; 68 women); or caesarean section (RR 1.00, 95% CI 0.57 to 1.77; 68 women). High-fibre versus standard-fibre diet (one trial): no primary outcomes reported. Ethnic-specific versus standard healthy diet (one trial): no clear differences observed for: large-for-gestational age (RR 0.14, 95% CI 0.01 to 2.45; 20 infants); neonatal composite adverse outcome (no events; 20 infants); gestational hypertension (RR 0.33, 95% CI 0.02 to 7.32; 20 women); or caesarean birth (RR 1.20, 95% CI 0.54 to 2.67; 20 women). Secondary outcomes For secondary outcomes assessed using GRADE no differences were observed: between a low-moderate and moderate-high GI diet for induction of labour (RR 0.88, 95% CI 0.33 to 2.34; one trial, 63 women; low-quality evidence); or an energy-restricted and no energy-restricted diet for induction of labour (RR 1.02, 95% CI 0.68 to 1.53; one trial, 114 women, low-quality evidence) and neonatal hypoglycaemia (average RR 1.06, 95% CI 0.48 to 2.32; two trials, 408 infants; very low-quality evidence).Few other clear differences were observed for reported outcomes. Longer-term health outcomes and health services use and costs were largely not reported. AUTHORS'
CONCLUSIONS: Evidence from 19 trials assessing different types of dietary advice for women with GDM suggests no clear differences for primary outcomes and secondary outcomes assessed using GRADE, except for a possible reduction in caesarean section for women receiving a DASH diet compared with a control diet. Few differences were observed for secondary outcomes.Current evidence is limited by the small number of trials in each comparison, small sample sizes, and variable methodological quality. More evidence is needed to assess the effects of different types of dietary advice for women with GDM. Future trials should be adequately powered to evaluate short- and long-term outcomes.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28236296      PMCID: PMC6464700          DOI: 10.1002/14651858.CD009275.pub3

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  102 in total

1.  Comparison of the effect of saturated and monounsaturated fat on postprandial plasma glucose and insulin concentration in women with gestational diabetes mellitus.

Authors:  S Ilic; L Jovanovic; D J Pettitt
Journal:  Am J Perinatol       Date:  1999       Impact factor: 1.862

2.  Maternal carbohydrate intake and pregnancy outcome.

Authors:  James F Clapp
Journal:  Proc Nutr Soc       Date:  2002-02       Impact factor: 6.297

3.  A randomised controlled trial of dietary energy restriction in the management of obese women with gestational diabetes.

Authors:  A Rae; D Bond; S Evans; F North; B Roberman; B Walters
Journal:  Aust N Z J Obstet Gynaecol       Date:  2000-11       Impact factor: 2.100

4.  Increasing prevalence of gestational diabetes mellitus (GDM) over time and by birth cohort: Kaiser Permanente of Colorado GDM Screening Program.

Authors:  Dana Dabelea; Janet K Snell-Bergeon; Cynthia L Hartsfield; Kimberly J Bischoff; Richard F Hamman; Robert S McDuffie
Journal:  Diabetes Care       Date:  2005-03       Impact factor: 19.112

5.  Higher carbohydrate intake is associated with decreased incidence of newborn macrosomia in women with gestational diabetes.

Authors:  M Romon; M C Nuttens; A Vambergue; O Vérier-Mine; S Biausque; C Lemaire; P Fontaine; J L Salomez; R Beuscart
Journal:  J Am Diet Assoc       Date:  2001-08

6.  Effect of a high monounsaturated fatty acid diet on blood pressure and glucose metabolism in women with gestational diabetes mellitus.

Authors:  F F Lauszus; O W Rasmussen; J E Henriksen; J G Klebe; L Jensen; K S Lauszus; K Hermansen
Journal:  Eur J Clin Nutr       Date:  2001-06       Impact factor: 4.016

7.  Advice that includes food sources of unsaturated fat supports future risk management of gestational diabetes mellitus.

Authors:  Lynda J Gillen; Linda C Tapsell
Journal:  J Am Diet Assoc       Date:  2004-12

Review 8.  The principles of dietary management of gestational diabetes: reflection on current evidence.

Authors:  A Dornhorst; G Frost
Journal:  J Hum Nutr Diet       Date:  2002-04       Impact factor: 3.089

Review 9.  Metformin therapy and diabetes in pregnancy.

Authors:  David Simmons; Barry N J Walters; Janet A Rowan; H David McIntyre
Journal:  Med J Aust       Date:  2004-05-03       Impact factor: 7.738

Review 10.  Gestational diabetes and the incidence of type 2 diabetes: a systematic review.

Authors:  Catherine Kim; Katherine M Newton; Robert H Knopp
Journal:  Diabetes Care       Date:  2002-10       Impact factor: 19.112

View more
  33 in total

Review 1.  Gestational Diabetes Mellitus.

Authors:  Emily D Szmuilowicz; Jami L Josefson; Boyd E Metzger
Journal:  Endocrinol Metab Clin North Am       Date:  2019-06-18       Impact factor: 4.741

2.  Identification of maternal continuous glucose monitoring metrics related to newborn birth weight in pregnant women with gestational diabetes.

Authors:  Song-Ying Shen; Justina Žurauskienė; Dong-Mei Wei; Nian-Nian Chen; Jin-Hua Lu; Ya-Shu Kuang; Hui-Hui Liu; Jean-Baptiste Cazier; Xiu Qiu
Journal:  Endocrine       Date:  2021-06-14       Impact factor: 3.633

Review 3.  Evidenced-Based Nutrition for Gestational Diabetes Mellitus.

Authors:  Amita Mahajan; Lois E Donovan; Rachelle Vallee; Jennifer M Yamamoto
Journal:  Curr Diab Rep       Date:  2019-08-31       Impact factor: 4.810

Review 4.  Nutrition therapy within and beyond gestational diabetes.

Authors:  Teri L Hernandez; Archana Mande; Linda A Barbour
Journal:  Diabetes Res Clin Pract       Date:  2018-04-19       Impact factor: 5.602

5.  Recurrent gestational diabetes : Breaking the transgenerational cycle with lifestyle modification.

Authors:  Thomas Liney; Nishel M Shah; Natasha Singh
Journal:  Wien Klin Wochenschr       Date:  2022-02-11       Impact factor: 1.704

Review 6.  Treatments for women with gestational diabetes mellitus: an overview of Cochrane systematic reviews.

Authors:  Ruth Martis; Caroline A Crowther; Emily Shepherd; Jane Alsweiler; Michelle R Downie; Julie Brown
Journal:  Cochrane Database Syst Rev       Date:  2018-08-14

7.  Impact of dietary counseling on the perception of diet in patients with gestational diabetes mellitus.

Authors:  Miyako Kishimoto; Ryutaro Kato; Yoko Oshiba
Journal:  Diabetol Int       Date:  2020-07-09

Review 8.  The importance of nutrition in pregnancy and lactation: lifelong consequences.

Authors:  Nicole E Marshall; Barbara Abrams; Linda A Barbour; Patrick Catalano; Parul Christian; Jacob E Friedman; William W Hay; Teri L Hernandez; Nancy F Krebs; Emily Oken; Jonathan Q Purnell; James M Roberts; Hora Soltani; Jacqueline Wallace; Kent L Thornburg
Journal:  Am J Obstet Gynecol       Date:  2021-12-27       Impact factor: 10.693

9.  Interventions during pregnancy to prevent preterm birth: an overview of Cochrane systematic reviews.

Authors:  Nancy Medley; Joshua P Vogel; Angharad Care; Zarko Alfirevic
Journal:  Cochrane Database Syst Rev       Date:  2018-11-14

10.  Dietary Blueberry and Soluble Fiber Supplementation Reduces Risk of Gestational Diabetes in Women with Obesity in a Randomized Controlled Trial.

Authors:  Arpita Basu; Du Feng; Petar Planinic; Jeffrey L Ebersole; Timothy J Lyons; James M Alexander
Journal:  J Nutr       Date:  2021-05-11       Impact factor: 4.687

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.